Abstract
The COVID-19 pandemic forced all oncologists worldwide to reduce patient contacts to decrease risk of exposure to the virus, and to reallocate resources to provide necessary COVID-19 care. We realized such a reduction of site-visits in our center by adapting the dosing schedules of nivolumab and pembrolizumab monotherapy and consolidation therapy or adjuvant durvalumab for patients with stage III and IV non-small cell lung cancer (NSCLC). Here we report the toxicity of the adapted dose versus the standard dose schedule in a real-world NSCLC population.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
